SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending with community members citing its privacy features and potential as a hedge against Bitcoin. Some are drawing comparisons to Bitcoin's early days and anticipating a significant price increase. The conversation includes discussion of Zcash's upcoming anniversary and potential for new highs.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp. - Warrants (27/02/2029)

Critical Metals Corp. warrants ($CRMLW) are trending as traders discuss potential for significant gains relative to the common stock, especially with resource estimate updates and possible short squeezes. Community members highlight the warrants' trading flexibility during extended hours and their potential for higher percentage gains compared to the common stock ($CRML). Some are also pointing to the EU waking up to critical metals, which may be a catalyst.

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

NewcelX Ltd.

NCEL is trending due to its recent merger with Kadimastem and subsequent ticker change, although some investors express concern over the reverse split and its impact on share value. Community members are actively discussing the potential for a short squeeze and the stock's future price, while also referencing technical indicators and potential broker issues related to the split. The merger's strategic implications and the combined company's prospects are also being debated.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending amid increased discussion of potential collaborations with ExxonMobil on carbon capture technology for data centers, sparked by a recent conference call. The community is focused on interpreting statements made during the call and the potential impact of any partnership on FCEL's future prospects, especially when compared to sector peers. Interest is also fueled by the rising demand for clean energy solutions to power AI.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to a recent volume spike and increased attention on its micro float. Community members are discussing the potential for a significant price increase, drawing comparisons to other low-float stocks that have experienced parabolic runs. The stock's recent price action and the possibility of a squeeze are also key talking points.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders assess market volatility amid mixed signals, including concerns about potential pullbacks and upcoming earnings reports from major tech companies. Community discussions revolve around hedging strategies and interpreting market indicators, with some anticipating a possible market correction or a volatility spike due to geopolitical tensions or economic uncertainty. The potential impact of upcoming economic data and policy decisions on market stability is also a key focus.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending due to the appointment of a new CFO from Johnson & Johnson, sparking optimism about the company's future financial strategies. Community members are actively discussing the potential impact on the company's valuation and long-term prospects, especially with upcoming earnings and existing discussions of Medicare coverage for XPHOZAH.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate earnings, with community discussions focused on the company's growth potential and valuation. Some are drawing comparisons to other tech giants like Nvidia and Meta, while others highlight Palantir's integration with military applications and potential for long-term contracts. Anticipation is building for a potential stock split, though opinions vary regarding a possible post-earnings pullback.

Propy is a decentralized real-estate market place backed by superior blockchain infrastructure to facilitate real-time unified transaction in order to reduce fraud and redundancy. Propy is the world’s first international real-estate marketplace.

Propy

Propy ($PRO) is trending as traders discuss recent price fluctuations and potential for future growth. Community members are actively debating entry and exit points, with some expressing frustration over volatility, while others highlight Propy's potential as a Real World Asset (RWA) project on the Ethereum blockchain and its association with real estate transactions. The conversation also includes speculation about market manipulation and possible upcoming news catalysts.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Recent community discussion around MNKD centers on Oppenheimer's raised price target and speculation regarding a potential deal with Dexcom and pediatric approval for Afrezza. Increased trading volume has some investors suggesting a possible short squeeze. Others express concern about the company's performance and CEO, citing past failures and the need for new catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's  What You Should Know

The consensus price target hints at a 63.6% upside potential for Oruka Therapeutics, Inc. (ORKA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MoonLake Immunotherapeutics shares crashed nearly 90% to record its worst session ever on Monday, as analysts downgraded the stock after the company announced late-stage trial results of its lead drug, sonelokimab, for the treatment of moderate-to-severe hidradenitis suppurativa (HS).By the end of the session, the stock had dropped to $6.25, marking its lowest levels in over three years, before gaining approximately 4.7% in after-hours trading.BTIG downgraded MoonLake to 'Neutral' from 'Buy' and removed the stock from its list of top picks for the second half of the year, saying sonelokimab failed to show differentiation in the Phase 3 VELA-1 and VELA-2 trials. The analyst noted that the placebo-adjusted HiSCR75 results were “well into our worst case scenario” and did not demonstrate a clear efficacy advantage over Bimzelx.Jefferies analyst Clara Dong also downgraded the stock to 'Hold' from 'Buy' and reduced the price target to $8 from $65, citing a smaller commercial opportunity, a lower likelihood of approval despite the drug’s potential path forward, and lesser M&amp;A value.Wolfe Research double-downgraded MoonLake to 'Underperform' from 'Outperform' with a steep price target cut to $2 from $76, saying that even if sonelokimab eventually finds a path forward in HS, realizing stock value “will take too long and will be too tough.”&nbsp;The brokerage firm called the outcome a “surprising MoonLake fiasco,” comparing it to Acelyrin’s collapse after its own HS trial failure, noting that Acelyrin’s stock never rebounded despite later-stage programs in PsA and TED.Leerink Partners highlighted Oruka Therapeutics as a likely beneficiary, noting that its drug, ORKA-002, with a mechanism similar to Bimzelx, could gain traction following MoonLake’s results.&nbsp;On Stocktwits, retail sentiment for MoonLake was ‘extremely bullish’ amid a 4,650% surge in 24-hour message volume.One user expressed confidence in MoonLake’s leadership and long-term outlook, stating that the company has a strong management team and a promising future, with potential for eventual FDA approval.<stembedurl>https://stocktwits.com/HitNRun79/message/630422460</stembedurl>Another user noted that the trial results, while not ideal, still showed meaningful efficacy. They suggested that the sharp decline in the stock was driven more by fear and short-seller activity than by fundamentals, and added that they had taken a position in the stock following the selloff.<stembedurl>https://stocktwits.com/freshstart2021/message/630421221</stembedurl><a href="https://stocktwits.com/symbol/MLTX">MoonLake’s stock</a> has declined 88.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades

Wolfe Research compared MoonLake’s setback to Acelyrin’s HS trial failure, noting that Acelyrin’s stock never rebounded despite later progress in other programs.

Equity

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

ORKA
Oruka Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ORKA News

ORKAOruka Therapeutics Inc.